{"id":"drug-carfilzomib-dexamethasone","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Anemia"},{"rate":"25-35","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Nausea"},{"rate":"20-30","effect":"Dyspnea"},{"rate":"15-25","effect":"Peripheral neuropathy"},{"rate":"5-10","effect":"Cardiac toxicity (heart failure)"},{"rate":"20-30","effect":"Infection"},{"rate":"15-25","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carfilzomib is a selective proteasome inhibitor that binds irreversibly to the 20S proteasome, preventing degradation of pro-apoptotic proteins and inducing apoptosis in multiple myeloma cells. Dexamethasone, a glucocorticoid, potentiates carfilzomib's cytotoxic effects and provides immunomodulatory and anti-inflammatory benefits. The combination is synergistic in overcoming proteasome inhibitor resistance.","oneSentence":"Carfilzomib inhibits the proteasome to trigger cancer cell death, while dexamethasone is a corticosteroid that enhances anti-myeloma effects and reduces inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:04.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (relapsed or refractory)"},{"name":"Multiple myeloma (newly diagnosed)"}]},"trialDetails":[{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT05675449","phase":"PHASE1","title":"A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-12-14","conditions":"Multiple Myeloma","enrollment":59},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT06158841","phase":"PHASE3","title":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-05-19","conditions":"Multiple Myeloma","enrollment":380},{"nctId":"NCT04764942","phase":"PHASE1, PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":39},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT05651932","phase":"PHASE1","title":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"K36 Therapeutics, Inc.","startDate":"2023-02-22","conditions":"Multiple Myeloma, Myeloma, Myeloma Multiple","enrollment":125},{"nctId":"NCT03275285","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-10-25","conditions":"Plasma Cell Myeloma","enrollment":302},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04822337","phase":"PHASE1, PHASE2","title":"Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT03934684","phase":"PHASE4","title":"Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-16","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":101},{"nctId":"NCT04458831","phase":"","title":"A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-08-13","conditions":"Plasma Cell Myeloma","enrollment":583},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT03158688","phase":"PHASE3","title":"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-06-13","conditions":"Relapsed Multiple Myeloma, Refractory Multiple Myeloma","enrollment":466},{"nctId":"NCT04892446","phase":"PHASE2","title":"Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-11-09","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT02405364","phase":"PHASE2","title":"Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2014-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT05669989","phase":"PHASE2","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Plasma Cell Myeloma","enrollment":70},{"nctId":"NCT03530683","phase":"PHASE1","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-14","conditions":"Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":189},{"nctId":"NCT03224507","phase":"PHASE2","title":"Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-03-14","conditions":"Multiple Myeloma","enrollment":123},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02294357","phase":"PHASE2","title":"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-12","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT03155100","phase":"PHASE2","title":"Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines","status":"COMPLETED","sponsor":"Raija Silvennoinen","startDate":"2017-08-07","conditions":"Multiple Myeloma in Relapse","enrollment":15},{"nctId":"NCT03948035","phase":"PHASE3","title":"Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuerzburg University Hospital","startDate":"2018-08-28","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":576},{"nctId":"NCT02628704","phase":"PHASE2","title":"Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02336815","phase":"PHASE2","title":"Selinexor Treatment of Refractory Myeloma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-05-26","conditions":"Multiple Myeloma","enrollment":202},{"nctId":"NCT03416374","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-18","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":45},{"nctId":"NCT01813227","phase":"PHASE2","title":"A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2013-04","conditions":"Waldenstrom Macroglobulinemia","enrollment":7},{"nctId":"NCT03104270","phase":"PHASE2","title":"Combination Study for High Risk Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2017-03-13","conditions":"Multiple Myeloma","enrollment":13},{"nctId":"NCT04163107","phase":"PHASE1","title":"Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2020-01-07","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT04288765","phase":"PHASE3","title":"Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma","status":"WITHDRAWN","sponsor":"Grupo Cooperativo de Hemopatías Malignas","startDate":"2020-03-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT01402284","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-21","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT01989325","phase":"PHASE2","title":"A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-11","conditions":"Advanced Multiple Myeloma","enrollment":77},{"nctId":"NCT02047253","phase":"PHASE2","title":"Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-04","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":28},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT01351623","phase":"PHASE2","title":"Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-05-09","conditions":"Multiple Myeloma","enrollment":44},{"nctId":"NCT02257476","phase":"PHASE1","title":"Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-08","conditions":"Neoplasms, Malignancies","enrollment":22},{"nctId":"NCT02756663","phase":"PHASE2","title":"Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT01204164","phase":"PHASE1","title":"Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies","status":"COMPLETED","sponsor":"Tragara Pharmaceuticals, Inc.","startDate":"2010-08","conditions":"AML, ALL, Blast Crisis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kyprolis"],"phase":"marketed","status":"active","brandName":"Drug: Carfilzomib + Dexamethasone","genericName":"Drug: Carfilzomib + Dexamethasone","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carfilzomib inhibits the proteasome to trigger cancer cell death, while dexamethasone is a corticosteroid that enhances anti-myeloma effects and reduces inflammation. Used for Multiple myeloma (relapsed or refractory), Multiple myeloma (newly diagnosed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}